Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Ideaya Biosciences Inc (IDYA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/08/2025: IDYA (3-star) is a STRONG-BUY. BUY since 46 days. Profits (4.79%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $51.08
1 Year Target Price $51.08
| 10 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 59.52% | Avg. Invested days 45 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.85B USD | Price to earnings Ratio - | 1Y Target Price 51.08 |
Price to earnings Ratio - | 1Y Target Price 51.08 | ||
Volume (30-day avg) 13 | Beta 0.02 | 52 Weeks Range 13.45 - 44.42 | Updated Date 07/8/2025 |
52 Weeks Range 13.45 - 44.42 | Updated Date 07/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.65 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -5147.81% |
Management Effectiveness
Return on Assets (TTM) -21.84% | Return on Equity (TTM) -31.34% |
Valuation
Trailing PE - | Forward PE 4.65 | Enterprise Value 1186694337 | Price to Sales(TTM) 264.75 |
Enterprise Value 1186694337 | Price to Sales(TTM) 264.75 | ||
Enterprise Value to Revenue 169.53 | Enterprise Value to EBITDA -7.8 | Shares Outstanding 87582000 | Shares Floating 82376967 |
Shares Outstanding 87582000 | Shares Floating 82376967 | ||
Percent Insiders 0.91 | Percent Institutions 117.16 |
Upturn AI SWOT
Ideaya Biosciences Inc
Company Overview
History and Background
Ideaya Biosciences Inc. was founded in 2011 and is focused on discovering and developing targeted therapeutics for cancers using synthetic lethality. It has made significant strides in developing novel oncology drugs targeting specific genetic mutations and pathways.
Core Business Areas
- Synthetic Lethality Programs: Ideaya focuses on identifying and developing therapies that exploit synthetic lethality, where the simultaneous disruption of two genes leads to cell death. This approach is aimed at targeting cancer cells with specific genetic vulnerabilities.
- Oncology Drug Discovery: Ideaya is engaged in the discovery and development of small molecule inhibitors and other therapeutic modalities for cancer treatment. This includes research and clinical trials for various cancer types.
Leadership and Structure
The leadership team includes Yujiro S. Hata as CEO, and Gregory Vontz as CFO, along with a team of scientific and clinical experts. The organizational structure is composed of research and development, clinical operations, and administrative functions.
Top Products and Market Share
Key Offerings
- IDE196: A protein kinase C (PKC) inhibitor being developed for genetically defined cancers. It competes with other PKC inhibitors in clinical trials, but specific market share data is not publicly available. Competitors include companies developing similar PKC inhibitors or other therapies for the same cancer types.
- PARP1/2 Inhibitor IDEAYA/GSK (GSK14039116): PARP inhibitor in development for tumors with homologous recombination deficiency (HRD). Competitors include marketed PARP inhibitors from AstraZeneca, GSK, and others.
- MAT2A Inhibitor IDEAYA/GSK (GSK684): An investigational inhibitor of MAT2A, a component of the methionine salvage pathway that is overexpressed in certain tumors. Competitors include other MAT2A inhibitors in early development stages.
Market Dynamics
Industry Overview
The oncology drug market is a rapidly growing and highly competitive industry, driven by advancements in cancer biology and the development of targeted therapies. There is high demand for innovative treatments with improved efficacy and safety profiles.
Positioning
Ideaya is positioned as a precision medicine company focused on synthetic lethality approaches. Its competitive advantages lie in its novel drug discovery platform and its focus on genetically defined patient populations.
Total Addressable Market (TAM)
The global oncology market is expected to reach hundreds of billions of dollars. Ideaya is positioned to capture a portion of this market by targeting specific cancer subtypes with its precision medicine approach, focusing on patient populations that benefit from synthetic lethality approaches.
Upturn SWOT Analysis
Strengths
- Novel drug discovery platform
- Focus on synthetic lethality
- Experienced management team
- Strategic partnerships with larger pharmaceutical companies (GSK)
- Strong intellectual property portfolio
Weaknesses
- Clinical trial risk
- Reliance on partnerships for funding
- Limited commercial infrastructure
- Early stage pipeline
- Dependence on successful clinical trial outcomes
Opportunities
- Expansion of pipeline through internal discovery efforts
- Potential for accelerated approval pathways
- Partnering opportunities with larger pharmaceutical companies
- Expansion into new cancer indications
- Acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Competition from other oncology drug developers
- Regulatory hurdles
- Patent challenges
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- AZN
- GSK
- MRTX
- BLU
Competitive Landscape
Ideaya faces competition from established oncology companies and other emerging biotech firms. Its competitive advantage lies in its novel drug discovery platform and its focus on synthetic lethality approaches targeting niche patient populations. Its disadvantages include clinical trial risk.
Growth Trajectory and Initiatives
Historical Growth: Ideaya's growth has been driven by the advancement of its pipeline programs and the establishment of strategic partnerships with larger pharmaceutical companies.
Future Projections: Future growth depends on the successful completion of clinical trials and the potential for regulatory approval of its pipeline candidates. Analyst estimates depend on clinical data.
Recent Initiatives: Recent initiatives include advancing its IDE196 clinical program, expanding its synthetic lethality platform, and strengthening its partnership with GSK.
Summary
Ideaya Biosciences is a biotechnology company focused on precision medicine in oncology, leveraging synthetic lethality approaches. It has promising early-stage clinical programs and strategic partnerships that are working well. It needs to be aware of clinical trial risks, securing adequate funding, and intense competition from larger companies in the oncology space. Ideaya is currently an early-stage revenue company and is highly dependent on external clinical results and the progress of partnerships with other companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data may be subject to change. Market share estimates are approximate and based on available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ideaya Biosciences Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2019-05-23 | President, CEO & Director Mr. Yujiro S. Hata | ||
Sector Healthcare | Industry Biotechnology | Full time employees 131 | Website https://www.ideayabio.com |
Full time employees 131 | Website https://www.ideayabio.com | ||
IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung (SCLC) and MTAP-deletion urothelial cancer; IDE849, a DLL3 antibody drug conjugate inhibitor that is in Phase 1 clinical trial for the treatment of SCLC and neuroendocrine tumors; IDE275, a Werner Helicase inhibitor that is in Phase 1 clinical trial for patients having tumors with high microsatellite instability; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1/2 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD. It also develops preclinical programs, including IDE892, a MTA-cooperative PRMT5 inhibitor; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; and IDE251, a KAT6/7 inhibitor. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Merck, Biocytogen, Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.